A detailed history of Entry Point Capital, LLC transactions in Harrow Health, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 7,580 shares of HROW stock, worth $332,610. This represents 0.2% of its overall portfolio holdings.

Number of Shares
7,580
Previous 6,398 18.47%
Holding current value
$332,610
Previous $134 Million 99.75%
% of portfolio
0.2%
Previous 0.2%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.85 - $46.47 $24,644 - $54,927
1,182 Added 18.47%
7,580 $340,000
Q2 2024

Aug 13, 2024

BUY
$10.0 - $21.64 $45,150 - $97,704
4,515 Added 239.78%
6,398 $134 Million
Q1 2024

May 14, 2024

SELL
$9.3 - $13.23 $437 - $621
-47 Reduced 2.44%
1,883 $24.9 Million
Q4 2023

Feb 14, 2024

BUY
$8.1 - $16.36 $15,633 - $31,574
1,930 New
1,930 $21.6 Million

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.19B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.